VANNUCCHI, ALESSANDRO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 45.442
EU - Europa 30.147
AS - Asia 21.916
SA - Sud America 3.188
AF - Africa 707
OC - Oceania 505
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 101.913
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 44.898
RU - Federazione Russa 9.173
PL - Polonia 8.098
SG - Singapore 5.886
CN - Cina 5.222
IT - Italia 3.295
HK - Hong Kong 3.204
BR - Brasile 2.560
VN - Vietnam 2.329
IE - Irlanda 2.110
KR - Corea 2.066
SE - Svezia 1.790
DE - Germania 1.112
FI - Finlandia 1.023
FR - Francia 955
IN - India 737
GB - Regno Unito 725
UA - Ucraina 639
AU - Australia 482
JO - Giordania 463
CH - Svizzera 400
ID - Indonesia 333
CA - Canada 310
BD - Bangladesh 291
TR - Turchia 268
AR - Argentina 267
JP - Giappone 231
NL - Olanda 207
ES - Italia 192
IQ - Iraq 159
CI - Costa d'Avorio 133
MX - Messico 128
ZA - Sudafrica 117
PK - Pakistan 114
NG - Nigeria 103
EC - Ecuador 99
AT - Austria 95
EG - Egitto 85
PH - Filippine 68
CO - Colombia 61
MA - Marocco 61
SA - Arabia Saudita 61
BE - Belgio 51
TW - Taiwan 50
IR - Iran 49
MY - Malesia 47
PY - Paraguay 46
UZ - Uzbekistan 46
VE - Venezuela 46
CL - Cile 41
GR - Grecia 41
AE - Emirati Arabi Uniti 39
CZ - Repubblica Ceca 37
TN - Tunisia 37
DZ - Algeria 31
KE - Kenya 31
NP - Nepal 30
PE - Perù 30
IL - Israele 26
JM - Giamaica 25
KZ - Kazakistan 24
AL - Albania 23
BJ - Benin 22
DO - Repubblica Dominicana 22
ET - Etiopia 22
NZ - Nuova Zelanda 22
UY - Uruguay 22
RO - Romania 21
TH - Thailandia 20
BG - Bulgaria 18
HU - Ungheria 17
SK - Slovacchia (Repubblica Slovacca) 17
OM - Oman 16
LK - Sri Lanka 15
LT - Lituania 14
AZ - Azerbaigian 13
BO - Bolivia 13
LB - Libano 13
SC - Seychelles 12
BH - Bahrain 11
DK - Danimarca 11
NO - Norvegia 11
SN - Senegal 11
SY - Repubblica araba siriana 11
CR - Costa Rica 10
KG - Kirghizistan 10
KW - Kuwait 10
MU - Mauritius 10
BY - Bielorussia 9
QA - Qatar 9
RS - Serbia 9
GE - Georgia 8
HR - Croazia 8
PT - Portogallo 8
SI - Slovenia 8
SV - El Salvador 8
TT - Trinidad e Tobago 8
AM - Armenia 7
HN - Honduras 7
KH - Cambogia 7
Totale 101.790
Salva come PNG Salva come JPEG
Città #
Warsaw 8.054
Santa Clara 7.785
Ashburn 5.206
Fairfield 4.755
Singapore 4.189
Hong Kong 2.637
Woodbridge 2.164
Dublin 2.104
Seattle 2.045
Seoul 2.026
Chandler 1.852
Cambridge 1.812
Houston 1.781
Wilmington 1.581
Hefei 1.365
San Jose 1.210
Jacksonville 999
Beijing 872
Altamura 821
Lawrence 793
Ann Arbor 733
Ho Chi Minh City 727
Princeton 658
Los Angeles 606
Lauterbourg 597
Buffalo 595
The Dalles 572
Hanoi 563
Boston 467
Moscow 464
Helsinki 419
Florence 418
Melbourne 406
Dallas 394
Bern 380
Mumbai 380
Boardman 356
Council Bluffs 354
New York 353
Amman 328
San Diego 274
Medford 256
Milan 247
Jakarta 227
Munich 221
São Paulo 212
Kent 199
Shanghai 198
Clifton 172
Bremen 164
Tokyo 163
London 148
Frankfurt am Main 139
Abidjan 133
Dong Ket 128
Izmir 117
Chicago 111
Phoenix 107
Paris 105
Orem 103
Rome 103
Da Nang 102
Redondo Beach 102
Abuja 97
Turku 95
Lappeenranta 89
Norwalk 89
Barcelona 88
Haiphong 85
Toronto 82
Rio de Janeiro 80
Hillsboro 78
Montreal 74
Vienna 74
Brooklyn 72
Guangzhou 71
Falls Church 66
Bengaluru 65
Baghdad 60
Belo Horizonte 60
Chennai 58
Andover 54
Biên Hòa 52
Shenzhen 50
Atlanta 49
Pune 49
Tianjin 48
Amsterdam 47
Johannesburg 47
West Jordan 47
Yubileyny 47
Curitiba 46
Denver 46
Brussels 44
Manchester 43
San Francisco 43
Tashkent 43
Ankara 40
Guayaquil 40
Naples 40
Totale 69.810
Salva come PNG Salva come JPEG
Nome #
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management 2.049
JAK Inhibition with Ruxolitinib versus Best Available Therapyfor Myelofibrosis 511
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 429
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 383
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 376
HDAC1 controls CIP2A transcription in human colorectal cancer cells 353
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study. 350
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 340
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 340
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086 340
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 335
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 330
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 330
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). 329
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 325
Essential Thrombocythemia 322
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 322
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 321
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives 320
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 319
EZH2 mutational status predicts poor survival in myelofibrosis. 318
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 318
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN 317
A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. 314
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 313
Advances in understanding and management of myeloproliferative neoplasms 312
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 311
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 307
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. 304
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 302
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 301
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium 301
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 301
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 300
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 299
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 298
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 295
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 293
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study 289
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 289
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing 288
Chronic myeloproliferative neoplasms: a collaborative approach. 281
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 279
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis 278
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 276
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. 275
Cardiovascular events and intensity of treatment in polycythemia vera. 272
Effect of mutation order on myeloproliferative neoplasms 272
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis 271
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells 270
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. 270
Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells 265
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. 265
FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis. 264
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 262
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 259
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms 258
Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms. 258
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. 258
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 256
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 253
MPN Score 251
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis 251
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 246
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 244
[GM-CSF: its clinical administration; the treatment of aplasia] 243
Clinical significance of genetic aberrations in secondary acute myeloid leukemia 241
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 240
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 235
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis. 234
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 234
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 228
The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes. 227
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 226
JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone 225
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 220
First report of FIP1L1-PDGFR alpha-positive eosinophilic granulomatosis with polyangiitis 220
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 219
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 219
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 216
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial 216
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 211
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 211
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 211
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 208
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 208
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 207
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. 206
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 203
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 203
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 201
The european hematology association roadmap for european hematology research: A consensus document 201
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 199
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation 198
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 197
Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling, human myelofibrosis 196
A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS 195
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 195
A life-threatening ruxolitinib discontinuation syndrome 195
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 194
Totale 28.910
Salva come PNG Salva come JPEG
Categoria #
all - tutte 290.569
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 290.569
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021480 0 0 0 0 0 0 0 0 0 0 0 480
2021/20223.864 123 346 366 148 113 150 144 425 194 140 618 1.097
2022/20239.796 1.016 2.020 416 748 701 1.717 1.120 494 739 96 265 464
2023/20243.733 159 405 685 194 330 467 115 713 67 261 188 149
2024/202526.210 898 2.753 1.747 3.655 6.586 3.350 722 1.439 1.654 920 1.064 1.422
2025/202630.711 3.258 4.601 3.533 3.307 3.191 1.340 3.757 1.707 2.134 2.067 1.246 570
Totale 102.893